CY1116019T1 - Μεθοδος χρησης καταστολεων histone deacetylase και παρακολουθηση παραγοντων βιο-σημανσης σε θεραπεια συνδυασμου - Google Patents

Μεθοδος χρησης καταστολεων histone deacetylase και παρακολουθηση παραγοντων βιο-σημανσης σε θεραπεια συνδυασμου

Info

Publication number
CY1116019T1
CY1116019T1 CY20151100112T CY151100112T CY1116019T1 CY 1116019 T1 CY1116019 T1 CY 1116019T1 CY 20151100112 T CY20151100112 T CY 20151100112T CY 151100112 T CY151100112 T CY 151100112T CY 1116019 T1 CY1116019 T1 CY 1116019T1
Authority
CY
Cyprus
Prior art keywords
histone deacetylase
combination therapy
methods
bio
monitoring
Prior art date
Application number
CY20151100112T
Other languages
English (en)
Inventor
Shanthi Adimoolam
Joseph J Buggy
Darren Magda
Richard Miller
Original Assignee
Pharmacyclics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacyclics, Inc. filed Critical Pharmacyclics, Inc.
Publication of CY1116019T1 publication Critical patent/CY1116019T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Στην παρούσα παρέχονται μέθοδοι για την χρήση τουλάχιστον ενός καταστολέα histone deacetylase για την μείωση της δραστικότητας επισκευής κυτταρικού DNA, μέθοδοι για την παρακολούθηση της μείωσης της δραστικότητας επισκευής κυτταρικού DNA χρησιμοποιώντας τουλάχιστον ένα παράγοντα βίο-σήμανσης, μέθοδοι για την θεραπεία του καρκίνου με χρήση τουλάχιστον ενός καταστολέα histone deacetylase για την μείωση της δραστικότητας επισκευής κυτταρικού DNA σε θεραπεία συνδυασμού, μέθοδοι θεραπείας συνδυασμού όπου ο τουλάχιστον ένας καταστολέας histone deacetylase επεμβαίνει σε ένα μηχανισμό επισκευής DNA που εμπλέκει RAD51, μέθοδοι για την πρόβλεψη μιας χρονικής περιόδου επαγωγής μεταξύ μιας πρώτης χορήγησης του τουλάχιστον ενός καταστολέα histone deacetylase και μιας δεύτερης χορήγησης τουλάχιστον μιας άλλης θεραπευτικής αγωγής, και φαρμακευτικές συνθέσεις για θεραπεία συνδυασμού.
CY20151100112T 2006-12-26 2015-02-02 Μεθοδος χρησης καταστολεων histone deacetylase και παρακολουθηση παραγοντων βιο-σημανσης σε θεραπεια συνδυασμου CY1116019T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87190006P 2006-12-26 2006-12-26
EP07869059.1A EP2099442B1 (en) 2006-12-26 2007-12-07 Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy

Publications (1)

Publication Number Publication Date
CY1116019T1 true CY1116019T1 (el) 2017-01-25

Family

ID=39588962

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151100112T CY1116019T1 (el) 2006-12-26 2015-02-02 Μεθοδος χρησης καταστολεων histone deacetylase και παρακολουθηση παραγοντων βιο-σημανσης σε θεραπεια συνδυασμου

Country Status (17)

Country Link
US (1) US9408816B2 (el)
EP (2) EP2626067A1 (el)
JP (2) JP2010514777A (el)
KR (2) KR20120090100A (el)
CN (1) CN101674820B (el)
AU (1) AU2007340129B2 (el)
CA (1) CA2674084C (el)
CY (1) CY1116019T1 (el)
DK (1) DK2099442T3 (el)
ES (1) ES2529147T3 (el)
NZ (1) NZ578428A (el)
PL (1) PL2099442T3 (el)
PT (1) PT2099442E (el)
RU (2) RU2446796C2 (el)
SI (1) SI2099442T1 (el)
WO (1) WO2008082856A1 (el)
ZA (1) ZA200905060B (el)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004230889B2 (en) 2003-04-07 2008-03-13 Pharmacyclics Llc Hydroxamates as therapeutic agents
ES2529147T3 (es) 2006-12-26 2015-02-17 Pharmacyclics, Inc. Método para usar los inhibidores de la histona deacetilasa y monitorear biomarcadores en la terapia de combinación
ES2374686T3 (es) 2007-05-14 2012-02-21 Historx, Inc. Separación en compartimentos por caracterización de píxel usando agrupamiento de datos de imágenes.
CA2690633C (en) * 2007-06-15 2015-08-04 Historx, Inc. Method and system for standardizing microscope instruments
CA2604317C (en) 2007-08-06 2017-02-28 Historx, Inc. Methods and system for validating sample images for quantitative immunoassays
CA2596204C (en) * 2007-08-07 2019-02-26 Historx, Inc. Method and system for determining an optimal dilution of a reagent
US7978258B2 (en) * 2007-08-31 2011-07-12 Historx, Inc. Automatic exposure time selection for imaging tissue
US9593376B2 (en) * 2008-06-02 2017-03-14 Institut Gustave Roussy Natural killer p30 (NKp30) dysfunction and the biological applications thereof
US9240043B2 (en) 2008-09-16 2016-01-19 Novartis Ag Reproducible quantification of biomarker expression
US8574829B2 (en) * 2009-03-31 2013-11-05 The Trustees Of The University Of Pennsylvania Methods of treating cancer with phenformin
US8603521B2 (en) 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
JP2013508458A (ja) * 2009-10-26 2013-03-07 ラモット・アット・テル−アヴィヴ・ユニヴァーシティ・リミテッド Ｆｔｓとｈｄａｃ阻害剤との組合せを用いたがん治療
EP2322658A1 (en) 2009-11-13 2011-05-18 Centre National de la Recherche Scientifique (CNRS) Signature for the diagnosis of breast cancer aggressiveness and genetic instability
WO2011103563A1 (en) * 2010-02-22 2011-08-25 Arno Therapeutics, Inc Methods and compositions for inhibiting and preventing the growth of malignant mast cells
CA3113343A1 (en) 2010-06-03 2011-12-08 Pharmacyclics Llc Use of inhibitors of bruton's tyrosine kinase (btk) in the treatment of follicular lymphoma
CA2835339A1 (en) 2011-05-18 2012-11-22 Centre National De La Recherche Scientifique (Cnrs) Signature for the diagnosis of cancer aggressiveness and genetic instability
RU2644635C2 (ru) * 2011-07-07 2018-02-13 Рисёрч Кансер Инститьют Оф Америка Системы, способы и составы для лечения рака
US8933078B2 (en) 2011-07-14 2015-01-13 Research Cancer Institute Of America Method of treating cancer with combinations of histone deacetylase inhibitors (HDAC1) substances
UA110853C2 (uk) * 2011-09-13 2016-02-25 Фармасайклікс, Інк. Лікарські форми інгібітора гістондеацетилази у комбінації з бендамустином та їхнє застосування
CA2860549A1 (en) 2012-01-05 2013-07-11 Christophe Cazaux Signature for the diagnosis of lung cancer aggressiveness and genetic instability
WO2013153532A1 (en) 2012-04-12 2013-10-17 University Of Saskatchewan Phthalocyanine compounds useful as reca inhibitors and methods of using same
EP3550031A1 (en) 2012-07-24 2019-10-09 Pharmacyclics, LLC Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
CN103191412B (zh) * 2013-04-01 2019-08-02 北京师范大学 Pa200和乙酰化介导核心组蛋白通过蛋白酶体降解
CN103310105A (zh) * 2013-06-13 2013-09-18 浙江加州国际纳米技术研究院绍兴分院 筛选非小细胞肺癌治疗疗效生物标记物的方法
CN103324846A (zh) * 2013-06-13 2013-09-25 浙江加州国际纳米技术研究院绍兴分院 结直肠癌症治疗预后生物标记物的筛选方法
JP6800750B2 (ja) 2013-08-02 2020-12-16 ファーマサイクリックス エルエルシー 固形腫瘍の処置方法
WO2015143400A1 (en) 2014-03-20 2015-09-24 Pharmacyclics, Inc. Phospholipase c gamma 2 and resistance associated mutations
RU2593342C1 (ru) * 2015-03-26 2016-08-10 Федеральное государственное бюджетное научное учреждение "Томский научно-исследовательский институт онкологии" (Томский НИИ онкологии) Способ комбинированного лечения немелкоклеточного рака легкого 1в-111 стадии с персонификацией адъювантной химиотерапии
WO2017149493A1 (en) * 2016-03-02 2017-09-08 The University Of Chicago Small molecules inhibitors of rad51
CA3023265A1 (en) * 2016-05-05 2017-11-09 Nantomics, Llc Checkpoint failure and methods therefor
EP4269427A3 (en) 2016-05-27 2023-11-22 Synthex, Inc. Protein interfaces
US11890292B2 (en) 2017-02-27 2024-02-06 Research Cancer Institute Of America Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
WO2018170457A1 (en) 2017-03-17 2018-09-20 Research Cancer Institute Of America Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
JP7265537B2 (ja) * 2017-09-11 2023-04-26 サイティアー セラピューティクス，インコーポレイティド Ｒａｄ５１阻害剤
GB2584210B (en) 2017-11-22 2022-03-16 Synthex Inc Peptides for inhibiting RAD51
KR102236356B1 (ko) * 2017-11-24 2021-04-05 주식회사 종근당 루푸스의 예방 또는 치료를 위한 조성물
KR20190118251A (ko) * 2018-04-10 2019-10-18 주식회사 종근당 건성안의 예방 또는 치료를 위한 조성물
CN109490543B (zh) * 2018-11-26 2021-08-31 复旦大学附属金山医院 一种预测胃肠间质瘤耐药性的试剂盒及其应用
KR20220103111A (ko) * 2019-10-18 2022-07-21 가부시키가이샤 바이오지프코드 이상 줄기 세포를 표적으로 하는 당뇨병 치료
GB201918413D0 (en) * 2019-12-13 2020-01-29 Z Factor Ltd Compounds and their use for the treatment of alpha1-antitrypsin deficiency
CN112485233B (zh) * 2020-11-03 2022-08-26 山东师范大学 一种检测去乙酰化酶用纳米传感器及其检测方法和应用
CN116196314B (zh) * 2023-05-04 2023-08-15 广州市妇女儿童医疗中心 Ri-1或其盐在制备防治胃肠道疾病的药物中的应用

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3126375A (en) 1964-03-24 Chioacyl
US2789118A (en) 1956-03-30 1957-04-16 American Cyanamid Co 16-alpha oxy-belta1, 4-pregnadienes
US2990401A (en) 1958-06-18 1961-06-27 American Cyanamid Co 11-substituted 16alpha, 17alpha-substituted methylenedioxy steroids
US3048581A (en) 1960-04-25 1962-08-07 Olin Mathieson Acetals and ketals of 16, 17-dihydroxy steroids
US3749712A (en) 1970-09-25 1973-07-31 Sigma Tau Ind Farmaceuti Triamcinolone acetonide esters and process for their preparation
BE794063A (fr) 1972-01-17 1973-07-16 Henkel & Cie Gmbh Anti-inflammatoires pour compositions cosmetiques
SE378109B (el) 1972-05-19 1975-08-18 Bofors Ab
US3996359A (en) 1972-05-19 1976-12-07 Ab Bofors Novel stereoisomeric component A of stereoisomeric mixtures of 2'-unsymmetrical 16,17-methylenedioxy steroid 21-acylates, compositions thereof, and method of treating therewith
SE378110B (el) 1972-05-19 1975-08-18 Bofors Ab
US3775656A (en) * 1972-05-22 1973-11-27 Aviat Inc Platform stabilization system
CH581818A5 (el) * 1973-02-27 1976-11-15 Cierva Juan J De
EP0084236A3 (en) 1981-12-22 1983-08-03 Fbc Limited Fungicidal heterocyclic compounds and compositions containing them
US4498038A (en) * 1983-02-15 1985-02-05 Malueg Richard M Stabilization system for soft-mounted platform
GB8518301D0 (en) 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
JPH0778017B2 (ja) 1985-12-28 1995-08-23 住友製薬株式会社 パルス的かつ持続放出性製剤
US4885314A (en) 1987-06-29 1989-12-05 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
US4782084A (en) 1987-06-29 1988-11-01 Merck & Co., Inc. HMG-COA reductase inhibitors
KR970006890B1 (ko) * 1987-10-20 1997-04-30 오스카 세이야꾸 가부시끼가이샤 페닐카르복시산 유도체 및 그 염
US5612059A (en) 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
JPH03215470A (ja) 1990-01-22 1991-09-20 Suntory Ltd プロピオン酸アミド誘導体，その製造法及びそれを有効成分として含有する除草剤
US5017381A (en) 1990-05-02 1991-05-21 Alza Corporation Multi-unit pulsatile delivery system
DE4124345A1 (de) * 1991-07-23 1993-01-28 Gruenenthal Gmbh Substituierte 3,4-dihydronaphthaline, diese verbindungen enthaltende arzneimittel und verfahren zur herstellung dieser verbindungen und arzneimittel
US5229135A (en) 1991-11-22 1993-07-20 Prographarm Laboratories Sustained release diltiazem formulation
US5260068A (en) 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
US5260069A (en) 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
DE4327365A1 (de) 1993-08-14 1995-02-16 Boehringer Mannheim Gmbh Verwendung von Phenolen und Phenolderivaten als Arzneimittel mit fibrinogensenkender Wirkung
US5448938A (en) * 1993-10-18 1995-09-12 Guardian Technologies International, Inc. Removable ballistic resistant armor seat cover and floor mat
US5567441A (en) 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
US5798119A (en) 1995-06-13 1998-08-25 S. C. Johnson & Son, Inc. Osmotic-delivery devices having vapor-permeable coatings
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US5958957A (en) * 1996-04-19 1999-09-28 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
ZA98376B (en) 1997-01-23 1998-07-23 Hoffmann La Roche Sulfamide-metalloprotease inhibitors
US5840329A (en) 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
KR100247563B1 (ko) 1997-07-16 2000-04-01 박영구 키랄3,4-에폭시부티르산및이의염의제조방법
JP2002501889A (ja) 1998-02-02 2002-01-22 トラスティーズ オブ タフツ カレッジ グルコース代謝を調節する方法、およびそれに関連する試薬
JP2002506075A (ja) 1998-03-09 2002-02-26 フォンダテッヒ・ベネルクス・ナムローゼ・フェンノートシャップ セリンペプチダーゼ調節剤
DE19823831A1 (de) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
DE19828114A1 (de) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
DE19828113A1 (de) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
US6211197B1 (en) 1998-10-07 2001-04-03 Merck Frosst Canada & Co. Prostaglandin receptor ligands
GB9904387D0 (en) 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
JP2003500772A (ja) * 1999-05-28 2003-01-07 グロバー、デイビッド、イー 自主的なセルフレベリング自動修正式安定台
US6718130B2 (en) * 1999-05-28 2004-04-06 David E. Grober Stabilized camera and marker buoy for media coverage of aquatic events
WO2001011369A1 (en) * 1999-08-10 2001-02-15 Pangene Corporation Cancer treatments and diagnostics utilizing rad51 related molecules and methods
AU6936500A (en) 1999-08-24 2001-03-19 Regents Of The University Of California, The Non-quinoline inhibitors of malaria parasites
US6921763B2 (en) * 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
KR20020088406A (ko) * 1999-09-17 2002-11-27 애보트 게엠베하 운트 콤파니 카게 치료제로서의 피라졸로피리미딘
US6541661B1 (en) 1999-11-23 2003-04-01 Methylgene, Inc. Inhibitors of histone deacetylase
JP4975941B2 (ja) 2000-09-29 2012-07-11 トポターゲット ユーケー リミテッド （ｅ）−ｎ−ヒドロキシ−３−（３−スルファモイル−フェニル）アクリルアミド化合物及びその治療用途
GB0023983D0 (en) 2000-09-29 2000-11-15 Prolifix Ltd Therapeutic compounds
KR100600550B1 (ko) * 2000-10-20 2006-07-13 에자이 가부시키가이샤 질소 함유 방향환 유도체
WO2002053775A2 (en) 2000-12-28 2002-07-11 Epidauros Biotechnologie Ag Identification of genetic determinants of polymorphic cyp3a5 expression
MXPA01013172A (es) * 2001-02-14 2002-08-21 Warner Lambert Co Inhibidores sulfonamida de metaloproteinasa de matriz.
MXPA03008560A (es) * 2001-03-22 2004-06-30 Abbot Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos.
WO2002083140A1 (en) 2001-04-10 2002-10-24 Merck & Co., Inc. Inhibitors of akt activity
AU2002251266A1 (en) 2001-04-10 2002-10-28 Merck Sharp And Dohme Limited Inhibitors of akt activity
WO2002083139A1 (en) 2001-04-10 2002-10-24 Merck & Co., Inc. Inhibitors of akt activity
WO2002083138A1 (en) 2001-04-10 2002-10-24 Merck & Co., Inc. Inhibitors of akt activity
BR0210650A (pt) * 2001-06-28 2004-10-05 Ucb Farchim Sa Tablete, e, uso do mesmo
US7247426B2 (en) * 2001-08-02 2007-07-24 Agilent Technologies, Inc. Classifying cancers
ITMI20011733A1 (it) * 2001-08-07 2003-02-07 Italfarmaco Spa Derivati dell'acido idrossamico inibitori degli enzimi istone deacetilasi, quali nuovi farmaci antiinfiammatori inibenti la sintesi di citoc
JP4238728B2 (ja) 2001-08-21 2009-03-18 アステラス製薬株式会社 ヒストンデアセチラーゼ阻害剤の医薬用途ならびにその抗腫瘍効果の評価方法
US20030166026A1 (en) * 2002-01-09 2003-09-04 Lynx Therapeutics, Inc. Identification of specific biomarkers for breast cancer cells
US20060078879A1 (en) 2002-02-04 2006-04-13 Epidauros Biotechnologie Ag Polymorphisms in the human gene for tpmt and their use in diagnostic and therapeutic applications
JPWO2003070691A1 (ja) 2002-02-21 2005-06-09 財団法人大阪産業振興機構 Ｎ−ヒドロキシカルボキサミド誘導体
US20040132825A1 (en) 2002-03-04 2004-07-08 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
US20050182256A1 (en) 2002-04-08 2005-08-18 Duggan Mark E. Inhibitors of akt activity
CA2480800C (en) 2002-04-08 2008-09-23 Mark T. Bilodeau Inhibitors of akt activity
AU2003226271B2 (en) 2002-04-08 2007-10-18 Merck Sharp & Dohme Corp. Fused quinoxaline derivatives as inhibitors of Akt activity
CA2480880C (en) 2002-04-08 2011-03-22 Merck & Co., Inc. Inhibitors of akt activity
BR0313371A (pt) 2002-08-02 2005-07-05 Argenta Discovery Ltd Composto, uso de um composto e método de tratamento de doença
EP1400806A1 (en) 2002-09-18 2004-03-24 G2M Cancer Drugs AG The use of molecular markers for the preclinical and clinical profiling of inhibitors of enzymes having histone deacetylase activity
US6769347B1 (en) * 2002-11-26 2004-08-03 Recon/Optical, Inc. Dual elevation weapon station and method of use
CN1777675A (zh) 2003-02-19 2006-05-24 安斯泰来制药有限公司 预测组蛋白去乙酰化酶抑制剂抗肿瘤效果的方法
AU2004230889B2 (en) 2003-04-07 2008-03-13 Pharmacyclics Llc Hydroxamates as therapeutic agents
CN1768031A (zh) * 2003-04-07 2006-05-03 Axys药物公司 作为治疗剂的异羟肟酸酯
PE20050206A1 (es) 2003-05-26 2005-03-26 Schering Ag Composicion farmaceutica que contiene un inhibidor de histona deacetilasa
GB0317466D0 (en) * 2003-07-25 2003-08-27 Univ Sheffield Use
ES2425083T3 (es) 2003-09-25 2013-10-11 Astellas Pharma Inc. Agente antitumoral que comprende FK228 como inhibidor de histona desacetilasa y doxorrubicina como inhibidor de topoisomerasa II
CA2549324A1 (en) 2003-12-12 2005-06-30 Bayer Pharmaceuticals Corporation Gene expression profiles and methods of use
US7368476B2 (en) 2004-04-07 2008-05-06 Pharmacyclics, Inc. Hydroxamates as therapeutic agents
PL1591109T3 (pl) 2004-04-30 2008-11-28 Topotarget Germany Ag Preparat zawierający inhibitor deacetylazy histonów wykazujący dwufazowe uwalnianie”
EP1761281A1 (en) 2004-06-04 2007-03-14 Pfizer Products Incorporated Method for treating abnormal cell growth
RU2271824C1 (ru) * 2004-08-18 2006-03-20 Ростовский научно-исследовательский онкологический институт МЗ РФ Способ лечения рака легкого
WO2006042035A2 (en) * 2004-10-07 2006-04-20 Pharmacyclics, Inc. Method of monitoring anti-tumor activity of an hdac inhibitor
WO2006101454A1 (en) * 2005-03-21 2006-09-28 S*Bio Pte Ltd Benzothiophene derivatives: preparation and pharmaceutical applications
ES2529147T3 (es) 2006-12-26 2015-02-17 Pharmacyclics, Inc. Método para usar los inhibidores de la histona deacetilasa y monitorear biomarcadores en la terapia de combinación
EA201201640A1 (ru) 2007-01-30 2013-09-30 Фармасайкликс, Инк. Способы определения устойчивости рака к ингибиторам гистондеацетилазы
EP2060565A1 (en) 2007-11-16 2009-05-20 4Sc Ag Novel bifunctional compounds which inhibit protein kinases and histone deacetylases
EP2110377A1 (en) 2008-04-15 2009-10-21 DAC S.r.l. Spirocyclic derivatives as histone deacetylase inhibitors
US8603521B2 (en) 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
UY34295A (es) * 2011-09-08 2013-04-30 Servier Lab Nuevo esquema de administración de la n-hidroxi -4- {2-[3- (n,ndimetilaminometil)benzofuran -2- ilcarbonilamino]etoxi}benzamida
UA110853C2 (uk) 2011-09-13 2016-02-25 Фармасайклікс, Інк. Лікарські форми інгібітора гістондеацетилази у комбінації з бендамустином та їхнє застосування
US10078105B2 (en) 2015-09-23 2018-09-18 Abb Schweiz Ag Electrical system with arc fault detection

Also Published As

Publication number Publication date
EP2626067A1 (en) 2013-08-14
AU2007340129A1 (en) 2008-07-10
CN101674820B (zh) 2013-09-25
EP2099442B1 (en) 2014-11-19
ZA200905060B (en) 2010-07-28
DK2099442T3 (en) 2015-02-16
EP2099442A4 (en) 2010-06-16
EP2099442A1 (en) 2009-09-16
RU2011148293A (ru) 2013-06-10
PL2099442T3 (pl) 2015-04-30
KR20090101362A (ko) 2009-09-25
RU2446796C2 (ru) 2012-04-10
RU2009126655A (ru) 2011-02-10
US20080153877A1 (en) 2008-06-26
NZ578428A (en) 2012-03-30
CA2674084C (en) 2013-05-14
JP5827706B2 (ja) 2015-12-02
SI2099442T1 (sl) 2015-03-31
US9408816B2 (en) 2016-08-09
KR20120090100A (ko) 2012-08-16
JP2010514777A (ja) 2010-05-06
AU2007340129B2 (en) 2012-02-02
PT2099442E (pt) 2015-02-10
WO2008082856A1 (en) 2008-07-10
ES2529147T3 (es) 2015-02-17
CA2674084A1 (en) 2008-07-10
JP2014139181A (ja) 2014-07-31
CN101674820A (zh) 2010-03-17

Similar Documents

Publication Publication Date Title
CY1116019T1 (el) Μεθοδος χρησης καταστολεων histone deacetylase και παρακολουθηση παραγοντων βιο-σημανσης σε θεραπεια συνδυασμου
CY1120961T1 (el) Δοσολογικες μορφες απο του στοματος που περιλαμβανουν αντιαιμοπεταλιακο παραγοντα και αναστολεα οξεος
CY1121065T1 (el) Αναστολεις ιβατ για την αγωγη ηπατικων νοσων
CY1121135T1 (el) Ενωσεις υποκατεστημενης τετρακυκλιnhς για την θεραπευτικη αγωγη φλεγμονωδων διαταραχων του δερματος
CY1120904T1 (el) Βελτιωμενη γελη τεστοστερονης και μεθοδος χρησεως στην αγωγη του υπογοναδισμου
EA201792191A1 (ru) Комбинированная терапия fgfr/pd-1 для лечения злокачественной опухоли
TN2011000239A1 (en) Hsp90 inhibitor combinations
UA118645C2 (uk) Спосіб комбінованої терапії раку наночастинками, що містять рапаміцин і альбумін
BRPI0712607A8 (pt) métodos de tratamento de acidente vascular cerebral
NO20091661L (no) Anvendelse av pegylert IL-10 for a behandle kreft
CR20110128A (es) Metodos, sistemas y productos para predecir la respuesta de las celulas tumorales a un agente terapeutico y tratar a un paciente de acuerdo con la respuesta predicha
CL2011000916A1 (es) Uso de una combinacion de un inhibidor de proteasoma epoxicetona peptidica o una sal farmaceutica aceptable del mismo, y uno o mas de otros agentes terapeuticos para tratar el cancer.
EA200870185A1 (ru) Комбинации ингибиторов ang2 и vegf
CL2008001124A1 (es) Formulacion farmaceutica que comprende al menos un derivado de acido lipoico y un reactivo formador de par ionico, util en el tratamiento del cancer.
EA201170521A1 (ru) Новые соединения
BRPI0814340A2 (pt) Método para tratar uma formação subterrânea, programa de computador, e, sistema para tratar uma formação subterrânea
EA201100609A1 (ru) Способы лечения воспаления
MX2015010791A (es) Metodos para tratar el cancer y prevenir la resistencia a farmacos.
BRPI0813402A2 (pt) Agente para evitar ou tratar um câncer resistente a trastuzumab, droga combinada, métodos para prevenir ou tratar câncer resistente a trastuzumab, para examinar a sensibilidade de um câncer expressando her2 a um inibidor de her2, para tratar um câncer em um animal julgado ter baixa sensibilidade a um inibidor de her2 e para triar uma droga para a profilaxia ou tratamento de um câncer resistente a trastuzumab, e, uso de um ou mais medicamentos.
BRPI0908635A8 (pt) composto, composição farmacêutica e método de tratamento de câncer
BRPI0921519A8 (pt) Forma de dosagem de fármaco sufentanil sólida embalada e método para prevenir a degradação oxidativa da referida forma de dosagem
CY1116216T1 (el) Μεθοδος θεραπειας ασθενειας αποθηκευσης γλυκογονου
BRPI0908168A2 (pt) composto, medicamento, inibidor de dipeptidil peptidase-iv, agente terapêutico para diabetes, e, método de tratamento de diabetes
BRPI0818323A2 (pt) composição farmacêutica, uso de uma composição farmacêutica, e, método para tratar câncer.
EA201170821A1 (ru) Энзастаурин для лечения рака